Estados Unidos - inglês - NLM (National Library of Medicine)

king bio inc. - equal volumes of each hpus ingredient in 10x, 30x, and 1lm potencies., adrenalinum, adrenocorticotrophin (30x), agrimonia eupatoria, flos, anacardium orientale, antimonium crudum, calcarea carbonica,  castanea sativa, flos, cortisone aceticum, fucus vesiculosus, hypothalamus, kali bichromicum, oleander, pituitarum posterium, sabadilla, staphysagria, thyroidinum., **“hpus” indicates the active ingredients are in the official homeopathic pharmacopeia of the united states., reference image:appetite and weight. - temporarily relieves symptoms contributing to:  excessive appetite  constitutional tendency to gain fat cravings for sweets and starches  water retention overeating  ravenous hunger  excess weight abdominal fat as per various homeopathic materia medicas. claims based on traditional homeopathic practice, not accepted medical evidence. these uses have not been evaluated by the fda, and product has not been clinically tested. reference image:appetite and weight.jpg  equal volumes of each hpus ingredient in 10x, 30x, and 1lm potencies. adrenalinum ................................increased appetite, indigestion adrenocorticotrophin (30x) ............. fat face, neck, and shoulders agrimonia eupatoria, flos .............................................cravings anacardium orientale ........................... empty feeling in stomach antimonium crudum ...........tendency to grow fat, constant hunger calcarea carbonica ......................ravenous hunger, abdominal fat castanea sativa, flos .............

Estados Unidos - inglês - NLM (National Library of Medicine)

nutritional specialties, inc. - foeniculum vulgare fruit (unii: j5w36y5wg8) (foeniculum vulgare fruit - unii:j5w36y5wg8), fucus vesiculosus (unii: 535g2abx9m) (fucus vesiculosus - unii:535g2abx9m), egg phospholipids (unii: 1z74184rgv) (egg phospholipids - unii:1z74184rgv), ammonium carbonate (unii: nj5vt0fklj) (ammonium cation - unii:54s68520i4), caulophyllum thalictroides root (unii: jtj6hh6yeh) (caulophyllum thalictroides root - unii:jtj6hh6yeh), galium aparine whole (unii: z4b6561488) (galium aparine - unii:z4b6561488), skim milk - to assist in weight loss.† †claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated. to assist in weight loss.† †claims based on traditional homeopathic practice, not accepted medical evidence. not fda evaluated.

Estados Unidos - inglês - NLM (National Library of Medicine)

eli lilly and company - tirzepatide (unii: oyn3cci6qe) (tirzepatide - unii:oyn3cci6qe) - zepbound® is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (bmi) of: - 30 kg/m2 or greater (obesity) or - 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease). limitations of use - zepbound contains tirzepatide. coadministration with other tirzepatide-containing products or with any glucagon-like peptide-1 (glp-1) receptor agonist is not recommended. - the safety and efficacy of zepbound in combination with other products intended for weight management, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. - zepbound has not been studied in patients with a history of pancreatitis [see warnings and precautions (5.5)] . zepbound is contraindicated in patients with: - a personal or family history of mtc or in patients with men 2 [see warnings and precautions (5.1)] . - known serious hypersensitivity to tirzepatide or any of the excipients in zepbound. serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with tirzepatide [see warnings and precautions (5.6) and adverse reactions (6.2)] . pregnancy exposure registry there will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to zepbound (tirzepatide) during pregnancy. pregnant patients exposed to zepbound and healthcare providers are encouraged to contact eli lilly and company at 1-800-lillyrx (1-800-545-5979). risk summary weight loss offers no benefit to a pregnant patient and may cause fetal harm. advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue zepbound when a pregnancy is recognized (see clinical considerations) . available data with tirzepatide in pregnant patients are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. in pregnant rats administered tirzepatide during organogenesis, fetal growth reductions and fetal abnormalities occurred at clinical exposure in maternal rats based on auc. in rabbits administered tirzepatide during organogenesis, fetal growth reductions were observed at clinically relevant exposures based on auc. these adverse embryo/fetal effects in animals coincided with pharmacological effects on maternal weight and food consumption (see data) . the estimated background risk of major birth defects and miscarriage for the indicated population is increased when compared to the general population. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations disease-associated maternal and/or embryo/fetal risk appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those with obesity or overweight, due to the obligatory weight gain that occurs in maternal tissues during pregnancy. data animal data in pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5 mg/kg tirzepatide [0.03-, 0.07-, and 0.5-fold the maximum recommended human dose (mrhd) of 15 mg once weekly based on auc] during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5 mg/kg. in pregnant rabbits given once weekly subcutaneous doses of 0.01, 0.03, or 0.1 mg/kg tirzepatide (0.01-, 0.06-, and 0.2-fold the mrhd) during organogenesis, pharmacologically mediated effects on the gastrointestinal system resulting in maternal mortality or abortion in a few rabbits occurred at all dose levels. reduced fetal weights associated with decreased maternal food consumption and body weights were observed at 0.1 mg/kg. in a pre- and post-natal study in rats administered subcutaneous doses of 0.02, 0.10, or 0.25 mg/kg tirzepatide twice weekly from implantation through lactation, f1 pups from f0 maternal rats given 0.25 mg/kg tirzepatide had statistically significant lower mean body weight when compared to controls from post-natal day 7 through post-natal day 126 for males and post-natal day 56 for females. risk summary there are no data on the presence of tirzepatide or its metabolites in animal or human milk, the effects on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zepbound and any potential adverse effects on the breastfed infant from zepbound or from the underlying maternal condition. contraception use of zepbound may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. this delay is largest after the first dose and diminishes over time. advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation with zepbound and for 4 weeks after each dose escalation [see drug interactions (7.2) and clinical pharmacology (12.2, 12.3)] . the safety and effectiveness of zepbound have not been established in pediatric patients. in zepbound clinical trials, 226 (9%) zepbound-treated patients were 65 years of age or older, and 13 (0.5%) zepbound-treated patients were 75 years of age or older at baseline. no overall differences in safety or effectiveness of zepbound have been observed between patients 65 years of age and older and younger adult patients. no dosage adjustment of zepbound is recommended for patients with renal impairment. in subjects with renal impairment including end-stage renal disease (esrd), no change in tirzepatide pharmacokinetics (pk) was observed [see clinical pharmacology (12.3)] . monitor renal function in patients reporting adverse reactions to zepbound that could lead to volume depletion [see warnings and precautions (5.3)] . no dosage adjustment of zepbound is recommended for patients with hepatic impairment. in a clinical pharmacology study in subjects with varying degrees of hepatic impairment, no change in tirzepatide pk was observed [see clinical pharmacology (12.3)] . important information you need to know before injecting zepbound read this instructions for use and the medication guide before using your zepbound pen and each time you get a refill. there may be new information. this information does not take the place of talking to your healthcare provider about your medical condition or treatment. talk to your healthcare provider about how to inject zepbound the right way. - zepbound is a single-dose prefilled pen. - zepbound is used 1 time each week. - inject under the skin (subcutaneously) only. - you or another person can inject into your stomach (abdomen) or thigh. - another person can inject into the back of your upper arm. guide to parts preparing to inject zepbound - is not frozen - is not cloudy - is colorless to slightly yellow - does not have particles step    4 - first click = injection started - second click = injection completed disposing of your used pen - put your used pen in an fda-cleared sharps disposal container right away after use. do not throw away (dispose of) pens in your household trash. - if you do not have an fda-cleared sharps disposal container, you may use a household container that is: - made of a heavy-duty plastic, - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, - upright and stable during use, - leak-resistant, and - properly labeled to warn of hazardous waste inside the container. - when your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. there may be state or local laws about how you should throw away used needles and syringes. for more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the fda's website at: http://www.fda.gov/safesharpsdisposal. - do not recycle your used sharps disposal container. storage and handling - store your pen in the refrigerator between 36°f to 46°f (2°c to 8°c). - you may store your pen at room temperature up to 86°f (30°c) for up to 21 days. if you store the pen at room temperature, do not return the pen to the refrigerator. - discard the pen if not used within 21 days after removing from the refrigerator. - do not freeze your pen. if the pen has been frozen, throw the pen away and use a new pen. - store your pen in the original carton to protect your pen from light. - the pen has glass parts. handle it carefully. if you drop the pen on a hard surface, do not use it. use a new pen for your injection. - keep your zepbound pen and all medicines out of the reach of children. commonly asked questions what if i see air bubbles in my pen? air bubbles are normal. what if my pen is not at room temperature? it is not necessary to warm the pen to room temperature. what if i unlock the pen and press the purple injection button before pulling off the gray base cap? do not remove the gray base cap. throw away the pen and get a new pen. what if there is a drop of liquid on the tip of the needle when i remove the gray base cap? a drop of liquid on the tip of the needle is normal. do not touch the needle. do i need to hold the injection button down until the injection is complete? this is not necessary, but it may help you keep the pen steady against your skin. i heard more than 2 clicks during my injection—2 loud clicks and 1 soft one. did i get my complete injection? some people may hear a soft click right before the second loud click. that is the normal operation of the pen. do not remove the pen from your skin until you hear the second loud click. i am not sure if my pen worked the right way. what if there is a drop of liquid or blood on my skin after my injection? this is normal. press a cotton ball or gauze over the injection site. do not rub the injection site. other information - if you have vision problems, do not use your pen without help from a person trained to use the zepbound pen. where to learn more - if you have questions or problems with your zepbound pen, contact lilly at 1-800-lilly-rx (1-800-545-5979) or call your healthcare provider. - for more information about the zepbound pen, visit our website at www.zepbound.com. marketed by: lilly usa, llc indianapolis, in 46285, usa zepbound is a trademark of eli lilly and company. copyright © 2023, eli lilly and company. all rights reserved. this instructions for use has been approved by the u.s. food and drug administration. revised: november 2023 zep-0002-pen-ifu-20231109 important information you need to know before injecting zepbound read this instructions for use before you start taking zepbound and each time you get a new vial. there may be new information. this information does not take the place of talking to your healthcare provider about your medical condition or your treatment. do not share your needles or syringes with other people. you may give other people a serious infection or get a serious infection from them. talk to your healthcare provider about how to inject zepbound the right way. - zepbound is a single-dose vial. - zepbound is used 1 time each week. - inject under the skin (subcutaneously) only. - you or another person may inject into your stomach (abdomen) or thigh. - another person can inject into the back of your upper arm. gather supplies needed to give your injection - 1 single-dose zepbound vial - 1 syringe and 1 needle, supplied separately (for example, use a 1 ml syringe and needle as recommended by your healthcare provider) - 1 alcohol swab - gauze - 1 sharps container for throwing away used needles and syringes. see “disposing of used needles and syringes” at the end of these instructions. note: the needle and syringe are not included. the needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this instructions for use. preparing to inject zepbound remove the vial from the refrigerator. check the vial label to make sure you have the right medicine and dose, and that it has not expired. make sure the medicine: - is not frozen - is not cloudy - is colorless to slightly yellow - does not have particles always use a new syringe and needle for each injection to prevent infections and blocked needles. do not reuse or share your syringes or needles with other people. you may give other people a serious infection or get a serious infection from them. wash your hands with soap and water. injecting zepbound - inject exactly as your healthcare provider has shown you. your healthcare provider should tell you if you should pinch the skin before injecting. - change (rotate) your injection site within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites. - do not inject where the skin has pits, is thickened, or has lumps. - do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin. - do not mix zepbound with any other medicine. - do not inject zepbound in the same injection site used for other medicines. - if you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. do not rub the area. - do not recap the needle. recapping the needle can lead to a needle stick injury. disposing of used needles and syringes - put your used needle and syringe in an fda-cleared sharps disposal container right away after use. do not throw away (dispose of) loose needles and syringes in your household trash. - if you do not have an fda-cleared sharps disposal container, you may use a household container that is: - made of a heavy-duty plastic, - can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out, - upright and stable during use, - leak-resistant, and - properly labeled to warn of hazardous waste inside the container. - when your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. there may be state or local laws about how you should throw away used needles and syringes. for more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the fda’s website at: http://www.fda.gov/safesharpsdisposal. - do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. do not recycle your used sharps disposal container. storing zepbound - store all unopened vials in the refrigerator at 36°f to 46°f (2°c to 8°c). - you may store the unopened vial at room temperature up to 86°f (30°c) for up to 21 days. - do not freeze. do not use if zepbound has been frozen. - store the vial in the original carton to protect from light. - throw away all opened vials after use, even if there is medicine left in the vial. keep zepbound vials, syringes, needles, and all medicines out of the reach of children. if you have any questions or problems with your zepbound, contact lilly at 1-800-lilly-rx (1-800-545-5979) or call your healthcare provider for help. marketed by: lilly usa, llc indianapolis, in 46285, usa zepbound is a registered trademark of eli lilly and company. copyright © 2024, eli lilly and company. all rights reserved. zep-0001-vl-ifu-20240328 this instructions for use has been approved by the u.s. food and drug administration. issued: march 2024

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

australian supplements - gymnema sylvestre, quantity: 43.75 mg (equivalent: gymnema sylvestre, qty 875 mg); plectranthus barbatus, quantity: 113.75 mg (equivalent: plectranthus barbatus, qty 3.981 g); garcinia gummi-gutta, quantity: 416.5 mg (equivalent: garcinia gummi-gutta, qty 4.165 g; equivalent: hydroxycitric acid, qty 250 mg) - capsule, hard - excipient ingredients: magnesium stearate; silicon dioxide; microcrystalline cellulose; maltodextrin; hypromellose; disodium edetate; potable water; potassium acetate; gellan gum - helps decrease/reduce body weight ; helps in the maintenance of a healthy body weight ; helps enhance/promote/increase body fat loss ; helps in the maintenance of lean body mass ; traditionally used in ayurvedic medicine to aid/assist/helps in the management of sugar cravings

Estados Unidos - inglês - NLM (National Library of Medicine)

bouari group, llc dba weight loss company, the - artemisia abrotanum flowering top (unii: qg07g580u0) (artemisia abrotanum flowering top - unii:qg07g580u0), anacardium occidentale fruit (unii: 4a10jr4e7e) (anacardium occidentale fruit - unii:4a10jr4e7e), arsenic trioxide (unii: s7v92p67ho) (arsenic cation (3+) - unii:c96613f5av), barium chloride dihydrate (unii: el5gj3u77e) (barium cation - unii:v645272hln), helleborus niger root (unii: 608dgj6815) (helleborus niger root - unii:608dgj6815), strychnos ignatii seed (unii: 1nm3m2487k) (strychnos ignati - helps improve diencephalic banking of fat for consumption by the body. helps improve diencephalic banking of fat for consumption by the body.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

sun herbal pty ltd - foeniculum vulgare, quantity: 22.2 mg (equivalent: foeniculum vulgare, qty 133.2 mg); zingiber officinale, quantity: 22.2 mg (equivalent: zingiber officinale, qty 133.2 mg); rehmannia glutinosa, quantity: 44.7 mg (equivalent: rehmannia glutinosa, qty 268.2 mg); cinnamomum cassia, quantity: 22.2 mg (equivalent: cinnamomum cassia, qty 133.2 mg; equivalent: coumarin, qty 2.1 microgram); wolfiporia cocos, quantity: 44.4 mg (equivalent: wolfiporia cocos, qty 266.4 mg); paeonia suffruticosa, quantity: 33.3 mg (eq - capsule, hard - excipient ingredients: hydrolysed gelatin; titanium dioxide; soluble maize starch - traditionally used in chinese medicine to tonify/nourish/strengthen/replenish kidneys/kidney-qi ; traditionally used in chinese medicine to warm and nourish/strenghten/tonify/enrich kidneys/kidney-yang

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

designs for vision aust pty ltd - 18142 - eyelid weight, external - a device placed on the outside of the eyelid to "lidload" and/or determine the appropriate size of an eyelid weight for implantation.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

surgical specialists instrument supply company pty ltd -

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

ecomed pty ltd - 37001 - measurer, patient height - a device used for measuring the height of infant to adult size patients. it can be, e.g. a wall-mounted graduated scale (ruler) or a free-standing vertical graduated rod with an adjustable cross-piece that is placed on the top of the patient's head. it may give analogue or digital readings

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

medeleq australia pty ltd - 37001 - measurer, patient height - a device for measuring height/length of the patient.